Incidence of HIV and HCV in people who inject drugs: a systematic and meta-analysis review protocol
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
StandardStandard
Yn: BMJ Open, Cyfrol 11, Rhif 1, e041482, 17.05.2023.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
HarvardHarvard
APA
CBE
MLA
VancouverVancouver
Author
RIS
TY - JOUR
T1 - Incidence of HIV and HCV in people who inject drugs: a systematic and meta-analysis review protocol
AU - Sharhani, Asaad
AU - Shushtari, Zahra Jorjoran
AU - Rahmani, Azam
AU - Armoon, Bahram
AU - Noroozi, Mehdi
AU - Ahounbar, Elaheh
AU - Karimi, Salah Eddin
AU - Higgs, Peter
PY - 2023/5/17
Y1 - 2023/5/17
N2 - Introduction HIV and hepatitis C virus (HCV) are majorhealth concerns globally. This systematic review and meta-analysis protocol study aims to estimate the incidenceof HIV and HCV among people who inject drugs (PWIDs)by reviewing studies that have applied mathematicalmodelling. The primary purpose of this systematic reviewis to identify and review mathematical modelling studies ofHIV and HCV incidence in PWIDs.Methods and analysis cohort, cross-sectional and clinicaltrial studies conducted to estimate the incidence ofHIV and HCV based on mathematical models or haveevaluated the effectiveness of mathematical models willbe considered for inclusion in the review. A comprehensivesearch applying a Cochrane approach will be used toidentify relevant primary studies, published betweenJanuary 2000 and July 2020, and indexed in PubMed,EMBASE, Opengrey, WOS, SCOPUS and Cochrane Librarywith no restriction on language. This protocol was preparedaccording to the Preferred Reporting Items for SystematicReview and Meta-Analysis Protocols (PRISMA-P). Studyselection and data extraction will be performed by twoindependent reviewers. Assessment of risk of bias will beimplemented using forms of the Critical Appraisal SkillsProgramme. Publication bias will be assessed by funnelplots, Begg’s and Egger’s tests. A meta-analysis will beconducted to answer the first research question, ‘What isthe incidence of HIV and HCV when applying mathematicalmodel in PWID?’. Clinical heterogeneity will be assessedby looking at the characteristics of participants, methodof diagnosis and case definitions in the included primarystudies. In addition, subgroup analyses will be conductedfor population and secondary outcomes.Ethics and dissemination There are no ethical issuesrelated to this study. The findings will be published in peer-reviewed scientific journals and presented at internationaland national conferences.
AB - Introduction HIV and hepatitis C virus (HCV) are majorhealth concerns globally. This systematic review and meta-analysis protocol study aims to estimate the incidenceof HIV and HCV among people who inject drugs (PWIDs)by reviewing studies that have applied mathematicalmodelling. The primary purpose of this systematic reviewis to identify and review mathematical modelling studies ofHIV and HCV incidence in PWIDs.Methods and analysis cohort, cross-sectional and clinicaltrial studies conducted to estimate the incidence ofHIV and HCV based on mathematical models or haveevaluated the effectiveness of mathematical models willbe considered for inclusion in the review. A comprehensivesearch applying a Cochrane approach will be used toidentify relevant primary studies, published betweenJanuary 2000 and July 2020, and indexed in PubMed,EMBASE, Opengrey, WOS, SCOPUS and Cochrane Librarywith no restriction on language. This protocol was preparedaccording to the Preferred Reporting Items for SystematicReview and Meta-Analysis Protocols (PRISMA-P). Studyselection and data extraction will be performed by twoindependent reviewers. Assessment of risk of bias will beimplemented using forms of the Critical Appraisal SkillsProgramme. Publication bias will be assessed by funnelplots, Begg’s and Egger’s tests. A meta-analysis will beconducted to answer the first research question, ‘What isthe incidence of HIV and HCV when applying mathematicalmodel in PWID?’. Clinical heterogeneity will be assessedby looking at the characteristics of participants, methodof diagnosis and case definitions in the included primarystudies. In addition, subgroup analyses will be conductedfor population and secondary outcomes.Ethics and dissemination There are no ethical issuesrelated to this study. The findings will be published in peer-reviewed scientific journals and presented at internationaland national conferences.
U2 - 10.1136/ bmjopen-2020-041482
DO - 10.1136/ bmjopen-2020-041482
M3 - Article
VL - 11
JO - BMJ Open
JF - BMJ Open
SN - 2044-6055
IS - 1
M1 - e041482
ER -